Replaces Prod. #: BML-CN244
Long acting antianginal drug that is enzymatically converted in the liver to yield the active metabolite SIN-1 (Prod. No. BML-CN245). NO releasing vasodilator.
Product Details
| Alternative Name: | N-(Ethoxycarbonyl)-3-(4-morpholinyl)sydnoneimine, Morsidomine, SIN-10 |
| |
| Formula: | C9H14N4O4 |
| |
| MW: | 242.2 |
| |
| CAS: | 25717-80-0 |
| |
| MI: | 14: 6234 |
| |
| Purity: | ≥98% (TLC) |
| |
| Identity: | Determined by NMR. |
| |
| Appearance: | White solid. |
| |
| Solubility: | Soluble in methanol. |
| |
| Shipping: | Ambient Temperature |
| |
| Long Term Storage: | -20°C |
| |
| Handling: | Protect from light. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Nitric oxide donor molsidomine attenuates psychotomimetic effects of the NMDA receptor antagonist MK-801: N. Pitsikas, et al.; J. Neurosci. Res.
84, 299 (2006),
Abstract;
Long-term treatment with the NO-donor molsidomine reduces circulating ICAM-1 levels in patients with stable angina: C. Van Hove, et al.; Atherosclerosis
180, 399 (2005),
Abstract;
Molsidomine, a nitric oxide donor and L-arginine protects against rhabdomyolysis-induced myoglobinuric acute renal failure: V. Chander & K. Chopra; Biochim. Biophys. Acta
1723, 208 (2005),
Abstract;
Intrarenal administration of molsidomine, a molecule releasing nitric oxide, reduces renal ischemia-reperfusion injury in rats: A. Rodriguez-Pena, et al.; Am. J. Transplant.
4, 1605 (2004),
Abstract;
Molsidomine: alternative approaches to treat myocardial ischemia: R.-E. Nitz & V.B. Fiedler; Pharmacotherapy
7, 28 (1987),
Abstract;
Heilmittelchemische Studien In Der Heterocyclischen Reihe 35. Mitteilung. Über Sydnonimine. I. Herstellung und Eigenschaften von Sydnonimin-Salzen: H.U. Daeniker & J. Druey; Helv. Chim. Acta 45, 2426 (1962),
Related Products
